BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 26033723)

  • 1. Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.
    Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Quale J; Landman D
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4856-60. PubMed ID: 26033723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
    Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
    Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of MIC and disk diffusion quality control guidelines for meropenem-vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination.
    Munson E; Huband MD; Castanheira M; Fedler KA; Flamm RK
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):324-328. PubMed ID: 29276104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
    Hecker SJ; Reddy KR; Totrov M; Hirst GC; Lomovskaya O; Griffith DC; King P; Tsivkovski R; Sun D; Sabet M; Tarazi Z; Clifton MC; Atkins K; Raymond A; Potts KT; Abendroth J; Boyer SH; Loutit JS; Morgan EE; Durso S; Dudley MN
    J Med Chem; 2015 May; 58(9):3682-92. PubMed ID: 25782055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.
    Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Landman D; Quale J
    Antimicrob Agents Chemother; 2015 Aug; 59(8):5029-31. PubMed ID: 26014931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.
    Castanheira M; Rhomberg PR; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.
    Castanheira M; Huband MD; Mendes RE; Flamm RK
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A sensitive and specific phenotypic assay for detection of metallo-β-lactamases and KPC in Klebsiella pneumoniae with the use of meropenem disks supplemented with aminophenylboronic acid, dipicolinic acid and cloxacillin.
    Giske CG; Gezelius L; Samuelsen Ø; Warner M; Sundsfjord A; Woodford N
    Clin Microbiol Infect; 2011 Apr; 17(4):552-6. PubMed ID: 20597925
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Hackel MA; Lomovskaya O; Dudley MN; Karlowsky JA; Sahm DF
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of Omadacycline and Other Tetracyclines Against Contemporary Gram-Negative Pathogens from New York City Hospitals.
    Iregui A; Landman D; Quale J
    Microb Drug Resist; 2021 Feb; 27(2):190-195. PubMed ID: 32580619
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of BAL30072 alone or combined with β-lactamase inhibitors or with meropenem against carbapenem-resistant Enterobacteriaceae and non-fermenters.
    Mushtaq S; Woodford N; Hope R; Adkin R; Livermore DM
    J Antimicrob Chemother; 2013 Jul; 68(7):1601-8. PubMed ID: 23449829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae.
    Livermore DM; Mushtaq S
    J Antimicrob Chemother; 2013 Aug; 68(8):1825-31. PubMed ID: 23580564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem-resistant Enterobacteriaceae.
    Jorgensen SCJ; Rybak MJ
    Pharmacotherapy; 2018 Apr; 38(4):444-461. PubMed ID: 29427523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem.
    Griffith DC; Sabet M; Tarazi Z; Lomovskaya O; Dudley MN
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens.
    Hornsey M; Phee L; Stubbings W; Wareham DW
    Int J Antimicrob Agents; 2013 Oct; 42(4):343-6. PubMed ID: 23837926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
    Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
    J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of the siderophore monosulfactam BAL30072 against contemporary Gram-negative pathogens from New York City, including multidrug-resistant isolates.
    Landman D; Singh M; El-Imad B; Miller E; Win T; Quale J
    Int J Antimicrob Agents; 2014 Jun; 43(6):527-32. PubMed ID: 24796217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.